Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
Colo-rectal CancerMetastatic Cancer
Interventions
DRUG

Regorafenib

"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."

DRUG

Cyclophosphamide

50 mg per os, daily, for 6 months

DRUG

Capecitabine

625mg/m²/orally twice daily continuously for 6 months

DRUG

Aspirin

75 mg orally and daily until progression

Trial Locations (3)

21000

Centre georges-François Leclerc, Dijon

25030

CHU de Besançon, Besançon

Unknown

Hôpital Nord Franche-Comté, Montbéliard

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Centre Hospitalier Universitaire de Besancon

OTHER